Strategic Partnerships Sen-Jam has a history of collaboration with contract manufacturers and investors to advance its anti-inflammatory and oral therapies, presenting opportunities for BD outreach to CMOs, strategic investors, and potential co-development partners.

Clinical Pipeline With an FDA-pending product and a multi-indication patent focused on pain and flu-like symptoms, there are avenues for licensing discussions, co-development, or early-access partnerships with pharma companies seeking novel anti-inflammatory approaches.

Financing Signals Recent investment from 5Horizons Capital and ongoing funding activity indicate readiness for clinical advancement and potential for co-investment or milestone-driven deals with growth-focused investors and biopharma partners.

Key Expertise Addition of a senior immunology expert to the Scientific Advisory Board and established industry collaborators suggest value in outreach to academic collaborations, advisory roles, or expert-led consulting engagements with larger partners.

Market Positioning Focus on repurposing existing molecules for novel combinations in inflammation positions Sen-Jam as a nimble partner for pharma companies seeking faster pathways to inflammation-related therapies and injectable formulations.